Sugi Predict

Sugi Predict / Compounds / SCHEMBL6926526

SCHEMBL6926526

SCHEMBL6926526

O=S(=O)(Nc1cccnc1)c1ccc2[nH]c(-c3ccccc3)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 1/20 0.57
▸ MMP9 P14780 1/20 0.57
▸ MMP8 P22894 1/20 0.57
▸ MMP13 P45452 1/20 0.57
▸ MAPT P10636 12/20 0.57
▸ TP53 P04637 7/20 0.57
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ CHEK2 O96017 1/20 0.51
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ LMNA P02545 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ STAT1 P42224 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ LDHA P00338 1/20 0.48
▸ EPHX2 P34913 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926099 0.82 MAPT (0.55) MMP2MMP9MMP8MMP13MAPT
SCHEMBL15793143 0.80 MAPT (0.63) MMP2MMP9MMP8MMP13MAPT
SCHEMBL12316825 0.79 MAPT (0.84) MMP2MMP9MMP8MMP13MAPT
SCHEMBL11370727 0.79 MAPT (0.62) MMP2MMP9MMP8MMP13MAPT
SCHEMBL6925701 0.79 MAPT (0.62) MMP2MMP9MMP8MMP13MAPT
SCHEMBL15792215 0.79 KDM4E (0.51) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL15792214 0.79 KDM4E (0.51) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL15792491 0.79 MEN1 (0.62) MMP2MMP9MMP8MMP13MAPT
SCHEMBL6926045 0.78 MAPT (0.67) MMP2MMP9MMP8MMP13MAPT
SCHEMBL22112944 0.78 MMP2 (0.64) MMP2MMP9MMP8MMP13MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 — — US disclosed
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 — — US disclosed
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 — — US disclosed
WO-2011011722-A1 SUBSTITUTED BENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS VANDERBILT UNIVERSITY (US) 2011-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS GRM4, GRIK4, GRIA4 MMP2 3229/4885MMP9 3590/4885MMP8 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.